title: [New drugs in the treatment of chronic hepatitis C].
abstract: OBJECTIVE
  To analyze the efficacy and safety of the new direct antiviral agents (DAA) that will become the new therapeutic arsenal for the treatment of hepatitis C.
  
  
  METHODS
  We carried out a research in the electronic database with the following criteria: phase II and III clinical trials (CT) published until February 2014. The Mesh term used was "chronic hepatitis C" and "therapy".Studies with boceprevir or telaprevir were excluded. For the analysis of efficacy, we evaluated the rate of Sustained Viral Response(SVR), and for the safety, side effects and safety-related discontinuations were analyzed.
  
  
  RESULTS
  We included 24 CT that include associations with ribavirine(RBV) with or without peginterferon (PegINF) and associations of several DAA. The results associated of daclatasvir with PegINF and RBV have not been very successful. On the contrary, sofosbuvir presents activity in all viral genotypes . Sofosbuvir may be administered in free PegINF regimens. Around 90% of naïve patients achieve sustained virological response (RVS) and 80% in previously treated. In relation to second wave of NS3/4A protease inhibitors, simeprevir has achieved RVS in 90% of naïve patients and close to 80% in previously treated.The main combination of DAA were sofosbuvir and daclatasvir and sofosbuvir and ledipasvir. Both have achieved SVR in 100% of patients who previously had virological failure after receiving a protease inhibitor regimen with boceprevir or telaprevir.
  
  
  CONCLUSIONS
  The new generation of AAD for the treatment of hepatitis C will lead to higher response rates in all subtypes of patients with lower complexity regimens and better tolerated.
authors.affiliation: Hospital Universitario de Valme. España.. rociojg85@hotmail.com.
authors.forename: R
authors.initials: R
authors.lastname: Jimenez Galan
authors.affiliation: Hospital Universitario de Valme. España.. angelalbacete@yahoo.es.
authors.forename: A
authors.initials: A
authors.lastname: Albacete Ramirez
authors.affiliation: Hospital Universitario de Valme. España.. patriciamonjeagudo@hotmail.com.
authors.forename: P
authors.initials: P
authors.lastname: Monje Agudo
authors.affiliation: Hospital Universitario de Valme. España.. yolandaborrego77@hotmail.com.
authors.forename: Y
authors.initials: Y
authors.lastname: Borrego Izquierdo
authors.affiliation: Hospital Universitario de Valme. España.. ralejandro.morillo.sspa@juntadeandalucia.es.
authors.forename: R
authors.initials: R
authors.lastname: Morillo Verdugo
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D016174:Hepacivirus / Q000187:drug effects / Q000201:enzymology; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases
chemical_list: D000998:Antiviral Agents; D017361:Viral Nonstructural Proteins; C084422:NS3 protein, hepatitis C virus; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases